A blood-based test (Freenome) may provide a new option for colorectal cancer (CRC) screening in the average-risk U.S.

Shares of Accenture plc (NYSE:ACN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-three ...

Big data is changing the game, and data analytics companies are shaping the future of business intelligence. Amid this ...

Despite DeepSeek and Qwen 2.5 disrupting the global tech sector, investors welcomed the impressive Q4 AI revenues from ...

We recently published a list of 10 AI Stocks Investors are Watching Closely. In this article, we are going to take a look at ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Accenture (ACN) closed the most recent trading day at $384.95, moving +1.1% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.51% for the day. At the same ...

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Accenture (ACN – Research Report) and Itron ...

Accenture (ACN) reachead $380.75 at the closing of the latest trading day, reflecting a +1.69% change compared to its last close.

In a report released today, Jason Kupferberg from Bank of America Securities maintained a Buy rating on Accenture (ACN – Research Report). The ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...